​

Corcept Therapeutics Ownership | Who Owns Corcept Therapeutics?

OverviewForecastRevenueFinancialsChartTranscripts

Corcept Therapeutics Ownership Summary

Corcept Therapeutics is owned by 73.90% institutional investors, 11.57% insiders, and 14.53% retail investors. Blackrock is the largest institutional shareholder, holding 16.09% of CORT shares. iShares Core S&P Small-Cap ETF is the top mutual fund, with 5.33% of its assets in Corcept Therapeutics shares.

CORT Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockCorcept Therapeutics73.90%11.57%14.53%
SectorHealthcare Stocks 42.53%10.81%46.67%
IndustryBiotech Stocks 45.24%10.75%44.01%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Blackrock16.54M16.09%$537.36M
Blackrock funding, inc. /de12.05M11.57%$1.00B
Vanguard group9.54M9.16%$792.63M
Ingalls & snyder7.70M7.39%$639.78M
Renaissance6.09M5.85%$506.09M
Parallel advisors3.87M3.72%$321.76B
State street2.97M2.85%$246.87M
Fmr2.20M2.12%$183.00M
Geode capital management1.93M1.86%$161.53M
Dimensional fund advisors lp1.89M1.82%$157.28M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Ingalls & snyder7.70M20.92%$639.78M
Tanaka capital management111.21K16.64%$9.24M
Checkpoint capital392.33K10.92%$32.61M
Parallel advisors3.87M5.89%$321.76B
Birchview capital, lp67.20K4.22%$5.58M
Livforsakringsbolaget skandia, omsesidigt113.16K3.58%$82.18M
S&t bank/pa111.34K2.60%$9.25M
Fas wealth partners308.32K1.74%$25.62M
Synergy asset management506.86K1.43%$39.61M
Lisanti capital growth68.27K1.39%$5.67M

Top Buyers

HolderShares% AssetsChange
Fmr2.20M0.01%844.99K
Norges bank834.59K0.01%834.59K
Jpmorgan chase849.86K0.00%587.05K
Ubs group549.94K0.01%442.90K
Pacer advisors390.56K0.08%384.90K

Top Sellers

HolderShares% AssetsChange
Novo---2.41M
Ikarian capital---994.50K
Kynam capital management, lp---585.90K
T. rowe price investment management24.44K0.00%-541.83K
Bank of america corp /de/174.85K0.00%-498.50K

New Positions

HolderShares% AssetsChangeValue
Norges bank834.59K0.01%834.59K$42.06M
Bridgewater associates, lp305.95K0.10%305.95K$25.43M
Brown capital management240.05K0.82%240.05K$19.95M
Tanaka capital management111.21K16.64%111.21K$9.24M
Fcf advisors38.96K0.43%38.96K$3.24M

Sold Out

HolderChange
Claris advisors, llc / mo /-6.00
Mendota financial group-7.00
Global financial private client-13.00
Nelson, van denburg & campbell wealth management group-16.00
Center for financial planning-23.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 2025427-0.93%76,942,4182.16%731.41%209-5.86%137-9.87%
Jun 30, 2025432-3.79%78,890,554-3.87%751.22%221-7.14%15410.79%
Mar 31, 202544914.83%82,236,144-2.40%781.19%23615.12%14015.70%
Dec 31, 202438312.98%84,233,711-3.36%811.15%20015.61%12014.29%
Sep 30, 202433511.67%87,110,973-2.41%841.12%17420.00%101-11.40%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
iShares Core S&P Small-Cap ETF5.61M5.33%-
Vanguard Total Stock Mkt Idx Inv2.83M2.69%-59.65K
Vanguard US Total Market Shares ETF2.83M2.68%213.93K
Vanguard Small Cap Index2.19M2.08%-13.82K
iShares Russell 2000 ETF2.03M1.91%-
Vanguard Small Cap Growth Index Inv1.23M1.17%-1.94K
Vanguard Institutional Extnd Mkt Idx Tr1.01M0.96%-440.96K
SPDR® Portfolio S&P 600™ Sm Cap ETF834.58K0.79%10.03K
Fidelity Small Cap Index819.47K0.78%2.47K
iShares S&P Small-Cap 600 Growth ETF812.12K0.77%-

Recent Insider Transactions

DateNameRoleActivityValue
Nov 25, 2025Guyer William Chief Development OfficerSell$364.07K
Nov 05, 2025Guyer William Chief Development OfficerSell$22.88K
Nov 05, 2025Guyer William Chief Development OfficerSell$488.56K
Nov 05, 2025Guyer William Chief Development OfficerSell$995.68K
Nov 03, 2025Lyon Joseph Douglas See RemarksSell$368.24K

Insider Transactions Trends

DateBuySell
2025 Q4-21
2025 Q3-31
2025 Q2-36
2025 Q1-22
2024 Q4-7

CORT Ownership FAQ

Who Owns Corcept Therapeutics?

Corcept Therapeutics shareholders are primarily institutional investors at 73.90%, followed by 11.57% insiders and 14.53% retail investors. The average institutional ownership in Corcept Therapeutics's industry, Biotech Stocks , is 45.24%, which Corcept Therapeutics exceeds.

Who owns the most shares of Corcept Therapeutics?

Corcept Therapeutics’s largest shareholders are Blackrock (16.54M shares, 16.09%), Blackrock funding, inc. /de (12.05M shares, 11.57%), and Vanguard group (9.54M shares, 9.16%). Together, they hold 36.82% of Corcept Therapeutics’s total shares outstanding.

Does Blackrock own Corcept Therapeutics?

Yes, BlackRock owns 16.09% of Corcept Therapeutics, totaling 16.54M shares as of Jun 2024. This represents 0.01% of BlackRock's total assets, with a market value of 537.36M$. In the last quarter, BlackRock decreased its holdings by -287K shares, a -1.71% change.

Who is Corcept Therapeutics’s biggest shareholder by percentage of total assets invested?

Ingalls & snyder is Corcept Therapeutics’s biggest shareholder by percentage of total assets invested, with 20.92% of its assets in 7.7M Corcept Therapeutics shares, valued at 639.78M$.

Who is the top mutual fund holder of Corcept Therapeutics shares?

iShares Core S&P Small-Cap ETF is the top mutual fund holder of Corcept Therapeutics shares, with 5.33% of its total shares outstanding invested in 5.61M Corcept Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools